Minaris Joins CIRM Industry Resource Partner Program

Philadelphia, PA — Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced that it has joined the California Institute for Regenerative Medicine (CIRM) Industry Resource Partner (IRP) Program.

Through its participation in the IRP Program, Minaris will serve as a resource to CIRM-funded researchers and companies, providing Cell & Gene Therapy CDMO services across the full development lifecycle from early-stage development through commercial manufacturing. Minaris offers integrated capabilities spanning viral vector development and manufacturing, cell and gene therapy process development, clinical and commercial manufacturing, and a comprehensive suite of biosafety and potency testing services.

“CIRM plays a critical role in advancing CGT and accelerating therapies to patients,” said Eytan Abraham, CTO and CCO of Minaris. “By joining the Industry Resource Partner Program, we look forward to supporting CIRM’s network with flexible, scalable solutions tailored to the unique needs of emerging and growing cell and gene therapy programs that need to reach patients quickly and efficiently while planning for commercial success.”

As a fit-for-purpose CDMO, Minaris Advanced Therapies is uniquely positioned to partner with innovators seeking both scientific expertise and operational agility. The company’s end-to-end service model is designed to reduce development risk, streamline technology transfer, and support successful progression from preclinical studies through late-stage clinical trials and commercialization.

The CIRM Industry Resource Partner Program connects CIRM-funded projects with experienced service providers to help accelerate development timelines, strengthen manufacturing and quality strategies, and ultimately bring transformative therapies to patients.

About Minaris

Minaris is a global cell and gene therapy (CGT) CDMO and multimodal biosafety testing organization. With more than 25 years of CGT development and manufacturing expertise and more than 40 years in biosafety testing, Minaris combines deep legacy experience with state-of-the-art GMP facilities as a fully U.S.-owned organization under new ownership and management, built for today’s evolving therapeutic landscape. Through its divisions, Minaris Advanced Therapies and Minaris Advanced Testing, the company supports innovators from IND through commercial supply and delivers GMP analytics, biosafety, viral clearance, and product characterization across CGT and biologics. With five global sites across three continents, Minaris is committed to helping partners bring more therapies to more patients worldwide. For more information, visit https://minaris.com or follow us on LinkedIn.